1. Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin- embedded human tissue biopsies. ten Haaf, Pscherer S, Fries K, Barth S, Gattenlöhner S, Tur MK.  Immunology Letters, Aug;166(2):65-78, 2015
  2. Brehm H, Hristodorov D, Pardo A, Mladenov R, Niesen J, Fischer R, Tur MK, Barth S. Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein. Cancer Lett., Sep 1;365(2):149-55, 2015
  3. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. Mabs. Fitting J, Blume T, Ten Haaf A, Blau A, Gattenlöhner S, Tur MK1, Barth S*. MAbs, 7(2):390-402, 2015
  4. Niesen J, Brehm H, Stein C, Berges N, Pardo A, Fischer R, Ten Haaf A, Gattenlöhner S, Tur MK, Barth S. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells. J Cancer Res Clin Oncol., Jun;141(6):1049-61, 2015
  5. Kunze K, Gamerdinger U, Leßig-Owlanj J, Sorokina M, Brobeil A, Tur MK, Blau W, Burchardt A, Käbisch A, Schliesser G, Kiehl M, Rosenwald A, Rummel M, Grimminger F, Hain T, Chakraborty T, Bräuninger A, Gattenlöhner S. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. Pathol Res Pract., Jun;210(6):369-76, 2014
  6. Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S. CD30 as a therapeutic target for lymphoma. BioDrugs., Apr;28(2):181-209, 2014
  7. Hussain A.F *., Tur MK *, Barth S. An Aptamer-siRNA Chimera Silences the Eukaryotic Elongation Factor 2 Gene and Induces Apoptosis in Cancers Expressing αvβ3 Integrin. Nucleic Acid Ther. Jun;23(3):203-12, 2013
  8. Tur MK, Etschmann B, Benz A, Leich E, Waller C, Schuh K, Rosenwald A, Ertl G, Kienitz A, Haaf AT, Bräuninger A, Gattenlöhner S. The 140-kD isoform of CD56 (NCAM1) directs the molecular pathogenesis of ischemic cardiomyopathy. Am J Pathol. Apr;182(4):1205-18, 2013
  9. Siepert EM, Gartz E, Tur MK, Delbrück H, Barth S, Büchs J. Short-chain fluorescent tryptophan tags for on-line detection of functional recombinant proteins. BMC Biotechnol. Sep 21;12:65, 2012
  10. Hussain A.F., Kampmeier F, von Felbert V, Merk HF, Tur MK *, Barth S *. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug Chem. Dec 21;22(12):2487-95, 2011
  11. Fitting J., Killian D., Junghanss C., Willenbrock S., Escobar H.M. Lange S., Nolte I., Barth S., Tur MK, Generation of recombinant antibody fragments that target canine dendritic cells by phage display technology. Vet Comp Oncol. Sep;9(3):183-95, 2011
  12. Tur MK, Huhn M, Jost E, Thepen T, Brümmendorf TH, Barth S. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model. Int J Cancer. Sep 1;129(5):1277-82, 2011
  13. Michaeli W*, Michaelis I, Gries T, Deichmann T, Junge K, Tur M.K., Polymergewirk für den Dünndarm. Kunststoffe (02)64-66, 2010
  14. Ribbert T., Thepen T., Tur MK, Fischer R., Huhn M., Barth S. Killing of activated macrophages by recombinant anti-CD64 single chain fragment-based ETA´ immunotoxins: Valency dependency in vitro, as well as in vivo in a chronic cutaneous inflammation model in hCD64 transgenic mice, British Journal of Dermatology, 163(2):279-86, 2010
  15. Thepen T., Huhn M., Melmer G., Tur MK, Barth S., Fcγ Receptor 1 (CD64), a Target Beyond Cancer, Current Pharmaceutical Design. 15(23):2712-8, 2009
  16. Deichmann T., Michaelis I., Junge K., Tur MK, Michaeli W., Gries T. Textile Composite Materials for small intestine replacement. AUTEX Res. J., Vol. 9, No 4, Dec 2009
  17. Hetzel  C.,  Bachran  C.,  Tur  MK,  Fuchs  H.,  Stöcker  M.  -  Improved  Immunotoxins  with  Novel Functional Elements, Current Pharmaceutical Design. 15(23):2700-11, 2009
  18. Tur MK, Neef I., Jäger G., Teubner A., Stöcker M., Melmer G. Barth S. - Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy, Current Pharmaceutical Design. 15(23):2693-9, 2009
  19. Tur MK, Neef I., Jost E., Galm O., Jäger G., Stöcker, M., Ribbert, M., Osieka R., Klinge S., Barth S.,Targeted Restoration of Downregulated DAPK2 Tumor Suppressor Activity Induces Apoptosis in Hodgkin Lymphoma cells, Journal of Immunotherapy, 32(5):431-41, 2009
  20. Wullner U., Neef I., Tur MK, Barth S. - Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery. Recent Patents on Anti-Cancer Drug Discovery. 4(1):1-8, 2009
  21. Wullner U., Neef I., Eller A., Kleines M., Tur MK *, Barth S.* - Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets. 8(7):554-65, 2008
  22. Stahnke B., Thepen T., Stöcker M., Rosinke R., Jost E., Fischer R., Tur MK, Barth S. - Granzyme B- H22(scFv), a Human Immunotoxin Targeting CD64 in Acute Myeloid Leukemia of Monocytic Subtypes. Mol. Cancer Ther. 7(9):2924-32, 2008
  23. Paetz A, Sack M, Thepen T, Tur M.K, Bruell D, Finnern R, Fischer R, Barth S. - Recombinant soluble human Fcgamma receptor I with picomolar affinity for immunoglobulin G. Biochem Biophys Res Commun. 338(4):1811-1817, 2005
  24. Klimka A, Tur MK, Huhn M, Bierfreund U, Terrada E, Fischer R, Finnern R, Barth S. - Measurement of antibody-membrane interactions by surface plasmon resonance. Int. J. Mol. Med. 14: 765-768, 2004
  25. Rothe A, Klimka A, Tur MK, Pfitzner T, Huhn M, Sasse S, Mallmann P, Engert A, Barth S. - Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines. Int. J. Mol. Med. 14: 729-735, 2004
  26. Matthey B, Borchmann P, Schnell R, Tawadros S, Lange H, Huhn M, Klimka A, Tur MK, Barth S, Engert A, Hansen HP. - Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int. J. Cancer. 10: 568-574, 2004
  27. Tur MK, Huhn M., Thepen T., Stöcker M., Krohn R., Vogel S., Jost E., Osieka R., van de Winkel J.G., Fischer R., Finnern F., Barth S. - Recombinant anti-CD64 single-chain immunotoxin exhibits specific cytotoxicity against Acute Myeloid Leukemia cells, Cancer Res. 63, 8414-8419, 2003
  28. Stöcker M., Tur MK, Sasse S., Krüßmann A., Barth S., Engert A. - Secretion of functional anti-CD30- Angiogenin immunotoxins into the supernatant of transfected 293T-cells, Protein Expr Purif. 28: 211- 219, 2003
  29. Tur MK, Rothe A., Huhn M., Goerres U., Klimka A., Stocker M., Engert A., Fischer R., Finnern R., Barth S. A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells, Int. J. Mol. Med. 11: 523-527, 2003
  30. Pfitzner T., Reiser M., Barth S., Borchmann O., Schulz H., Schinköthe T., Oberhäuser F., Wessels J., Tur, M.K., Diehl V. Engert A. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia, Ann Hematol 81: 258-266, 2002
  31. Huhn M., Sasse S., Tur MK, Matthey B., Schinköthe T., Rybak S., Barth S., Engert A. - Human Angiogenin Fused to Human CD30 Ligand Exhibits Specific Cytotoxicity against CD30-positive Lymphoma, Cancer Res. 61, 8737-8747, 2001
  32. Tur MK, Sasse S., Stöcker M., Djabelkhir K., Huhn M., Matthey B., Gottstein C., Engert A., Barth S., An anti-GD2 scFv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma cell lines, Int. J. Mol. Med. 8: 579-584, 2001
  33. Tur MK, Huhn M., Sasse S., Engert A., Barth S. - Selection of scFv Phages on Intact Cells Under Low pH Conditions Leads to a significant Loss of Insert-Free Phages, BioTechniques 30: 404-413, 2001
  34. Barth S., Weidenmüller U., Tur MK, Schmidt M.F.G., Engert A. - Combining Phage Display and Screening of cDNA Expression Libraries: A New Approach for Identifying The Target Antigen of an scFv Preselected by Phage Display, J. Mol. Biol. 301: 751-757, 2000

Book Chapters

  1. Barth S., Gattenlöhner S., Tur MK, Immunokinases. Fusion Protein Technologies for Biopharmaceuticals. Applications and Challenges. WILEY (2013) ISBN 978-0-470-64627-4
  2. Klinge U., Fiebeler A., Tur MK. Postoperative CRPS in inguinal hernia patients. In Hernia Repair Sequelae. Hrsg V Schumpelick, RJ Fitzgibbons, Springer-Verlag Heidelberg (2009), ISBN 978-3-642- 04552-3
  3. Tur MK & Barth S. – Immunotherapy. Encyclopedia of Cancer, Springer Berlin, 2nd ed., (2009) ISBN: 978-3-540-47648-1
  4. Weidenmüller U., Tur MK, Engert A., Barth S. - Detection of disease-related surface antigens by combining phage display and cDNA expression library screening. GENE CLONING & EXPRESSION TECHNOLOGIES, BioTechniques® Books/Eaton Publishing, 521-525 (2002) ISBN-13: 978- 1881299202



Mehmet Kemal Tur


  • Department of Experimental Pathology and Immunotherapy
    Institute of Pathology
    Justus-Liebig-University Giessen
  • COUNTRY Germany